2 results
Approved WMOCompleted
The primary objective of the study is to confirm the efficacy of aliskiren 75 mg, 150 mg and 300 mg in patients with essential hypertension by testing the hypothesis of superior reduction in mean sitting systolic blood pressure (msSBP) from baseline…
Approved WMOCompleted
The primary objectives of the Phase Ib portion of the study are as follows:* To assess the safety and tolerability of the combination of polatuzumab vedotin with bendamustine and rituximab (BR) or bendamustine and obinutuzumab (BG) when administered…